Kaitlyn R. Antonelli

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2021 · 182 citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Patients With Pancreatic and Biliary Cancer With<i>CDKN2A</i>Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2019 · 93 citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Patients With Non–Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Tareq Al Baghdadi, Elizabeth Garrett‐Mayer, Susan Halabi et al. · Targeted Oncology · 2020 · 43 citations

Medicine, Oncology, Pharmacology +12

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2019 · 32 citations

Medicine, Oncology, Pharmacology +17